Abstract:Background: Serine/arginine-rich splicing factor 9 (SRSF9) is a classical RNA-binding protein that is essential for regulating gene expression programs through its interaction with target RNA. Whether SRSF9 plays an essential role in colorectal cancer (CRC) progression and can serve as a therapeutic target is largely unknown. Here, we highlight new findings on the role of SRSF9 in CRC progression and elucidate the underlying mechanism. Methods: CRC cell lines and clinical tissue samples were used. qRT-PCR, Western blotting, immunohistochemistry (IHC), gain- and loss-of-function assays, animal xenograft model studies, bioinformatic analysis, methylated single-stranded RNA affinity assays, gene-specific m6A quantitative qRT-PCR, dual-luciferase reporter assays and RNA stability assays were performed in this study. Results: The expression level of SRSF9 was higher in CRC cell lines than that in an immortal human intestinal epithelial cell line. Overexpression of SRSF9 was positively associated with lymph node metastasis and Dukes stage. Functionally, SRSF9 promoted cell proliferation, migration and invasion in vitro and xenograft growth. The results of bioinformatic analysis indicated that DSN1 was the downstream target of SRSF9. In CRC cells and clinical tissue samples, the expression of SRSF9 was positively associated with the expression of DSN1. Knockdown of DSN1 partially inhibited the SRSF9-induced phenotype in CRC cells. Mechanistically, we further found that SRSF9 is an m6A-binding protein and that m6A modifications were enriched in DSN1 mRNA in CRC cells. Two m6A modification sites (chr20:36773619-36773620 and chr20:36773645-chr20:36773646) in the SRSF9-binding region (chr20:36773597-36773736) of DSN1 mRNA were identified. SRSF9 binds to DSN1 in an m6A motif- and dose-dependent manner. SRSF9 modulates the expression of DSN1 in CRC cells. Such expression regulation was largely impaired upon methyltransferase METTL3 knockdown. Moreover, knockdown of SRSF9 accelerated DSN1 mRNA turnover, while overexpression of SRSF9 stabilized DSN1 mRNA in CRC cells. Such stabilizing was also weakened upon METTL3 knockdown. Conclusion: Overexpression of SRSF9 was associated with lymph node metastasis and Dukes stage in CRC. Knockdown of DSN1 eliminated the effects by SRSF9 overexpression in CRC. Our results indicated that SRSF9 functions as an m6A-binding protein (termed "reader") by enhancing the stability of DSN1 mRNA in m6A-related manner. Our study is the first to report that SRSF9-mediated m6A recognition has a crucial role in CRC progression, and highlights SRSF9 as a potential therapeutic target for CRC management.

SRSF1 Prevents DNA Damage and Promotes Tumorigenesis Through Regulation of DBF4B Pre-mRNA Splicing.

SRSF6-regulated Alternative Splicing That Promotes Tumour Progression Offers a Therapy Target for Colorectal Cancer

SRSF10 Facilitates HCC Growth and Metastasis by Suppressing CD8+T Cell Infiltration and Targeting SRSF10 Enhances Anti-Pd-l1 Therapy

BCLAF1 and Its Splicing Regulator SRSF10 Regulate the Tumorigenic Potential of Colon Cancer Cells

High Expression of SRSF10 Promotes Colorectal Cancer Progression by Aberrant Alternative Splicing of RFC5

SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner

SRSF3 Functions As an Oncogene in Colorectal Cancer by Regulating the Expression of ArhGAP30

SRSF2 safeguards efficient transcription of DNA damage and repair genes

Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1

SRSF1 Modulates PTPMT1 Alternative Splicing to Regulate Lung Cancer Cell Radioresistance

SRSF2 transcriptional function maintains genome integrity during cell division

Targeting Splicing Factor SRSF6 for Cancer Therapy

SIRT1 Involved in the Regulation of Alternative Splicing Affects the DNA Damage Response in Neural Stem Cells.

Smad4 Sequestered in SFPQ Condensates Prevents TGF-β Tumor-Suppressive Signaling.

The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers

SRSF3 Suppresses RCC Tumorigenesis and Progression Via Regulating SP4 Alternative Splicing

Alternative splicing regulation by tumor suppressing subtransferable candidate 4: a pathway to tumor suppression

The impact of RNA binding motif protein 4-regulated splicing cascade on the progression and metabolism of colorectal cancer cells

PTBP1 and PTBP2 Impaired Autoregulation of SRSF3 in Cancer Cells

Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer

Silencing of long non-coding RNA SBDSP1 suppresses tumor growth and invasion in colorectal cancer.